期刊文献+

天芪平颤方治疗帕金森病运动症状临床观察 被引量:4

Clinical Observation of Tianqi Pingchan Formula in Treatment of Motor Symptoms of Parkinson's Disease
下载PDF
导出
摘要 目的:观察天芪平颤方化裁结合西药治疗帕金森(PD)的临床疗效。方法:98例患者随机分为验证组(49例)、对照组(49例),两组均常规服用西药,验证组加裁本方(服药3个月—停药1个月—服药3个月),共随访7个月,评估治疗前后UPDRS(I、II、III)评分、PIMS评分、中医证候等参数变化。结果:7个月随访时验证组UPDRS评分有改善,验证组用药后对运动症状的改善幅度较对照组优(P<0.05);PIMS评分,中医证候积分均有明显改善(P<0.05);7个月随访时,2组多巴等效剂量都有增加,但验证组左旋多巴等效剂量的升高明显低于对照组(P<0.05)。结论:天芪平颤方对PD运动症状有协助改善作用;天芪平颤方对PD运动患者生活质量有较好改善作用。 Ohjective : To observe the effect of Tianqi Pingchan Formula on treatment of PD non-motor symptoms. Methods : PD patients were randomly divided into test group ( 49 cases ) and control group ( 49 cases ). The test group was treated by Tianqi Pingehan Formula combined with conventional western medicine ( taken 3 months., stop 1 month, taken 3 months ). Te unified PD Rating Scale ( UPDRS ), PD- NMSQuest, PIMS assessment parameters were used in baseline,3-month and 7-month follow up. Result: The scores of UPDRS could improve in 7-month follow up, but the motor symptoms of the test group significantly improved compared with that of the control group ( P〈0.05 ). The scores of PIMS improved in the test group in 7-month follow up compared with baseline. The daily L-dopa equivalent dosage of two groups in 7-month follow up was washigher than that in the baseline, hut elevated dose in test group was significantly lower than that the control group (P〈0.05). Conclusion: Tianqi Pingchan Formula has possible effect on motor symptoms of PD and can help to improve the quality of life in patients with PD.
出处 《辽宁中医药大学学报》 CAS 2014年第7期99-101,共3页 Journal of Liaoning University of Traditional Chinese Medicine
基金 上海市科委基础研究重点项目(09JC1411000) 上海市级医院联合社区开展慢性病综合防治项目(SHDC12012320)
关键词 帕金森病 运动症状 天芪平颤方 Parkinson's disease motor symptoms Tianqi Pingchan Formula
  • 相关文献

参考文献5

二级参考文献32

  • 1巴茂文,刘振国.左旋多巴诱发异动症的病理生理机制研究进展[J].中华神经科杂志,2005,38(6):403-404. 被引量:23
  • 2Marsden CD, Fahn S. Movement disorders. London: Butterworth, 1982 : 96-122.
  • 3Hardie R J, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Braln,1984, 107 ( Pt 2 ) :487-506.
  • 4Van Gerpen JA, Kumar N, Bower JH, et al. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol, 2006, 63: 205- 209.
  • 5Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord, 2001,16:448-458.
  • 6Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson' s disease. N Engl J Med, 2004,351 : 2498 -2508.
  • 7Hagell P, Piccini P, Bjorklund A, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci,2002, 5:627-628.
  • 8Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med, 2001,344:710-719.
  • 9de la Fuente-Feruondez R, Sehulzer M, Mak E, et al. Presynaptic mechanisms of motor fluctuations in Parkinson' s disease: a probabilistic model. Brain,2004,127(Pt 4) :888-899.
  • 10Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol,2006,63 : 1756-1760.

共引文献686

同被引文献56

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部